Cannabis use as described by people with multiple sclerosis

Canadian Journal of Neurological Sciences

Volumn 30, Issue 3, 2003, Pages 201-205

  Page, Stacey A ^a   Verhoef, M J ^a   Stebbins, R A ^a   Metz, L M ^a   Levy, J C ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS;

ADULT; ANXIETY DISORDER; ARTICLE; CANADA; DEPRESSION; DISEASE ACTIVITY; DRUG USE; FEMALE; HUMAN; LEGAL ASPECT; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; SIDE EFFECT; SPASTICITY; SYMPTOM;

EID: 0043009728     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100002584     Document Type: Article

References (32)

1. Weiner HL. A 21 point unifying hypothesis on the etiology and treatment of multiple sclerosis. Can J Neurol Sci 1998: 25: 93-101.
2. Svenson LW, Woodhead SE, Platt GH. Regional variations in the prevalence rates of multiple sclerosis in the province of Alberta, Canada. Neuroepidemiology 1994: 13: 8-13.
3. Metz L. Multiple sclerosis: symptomatic therapies. Semin Neurol 1998: 18: 389-395.
4. Beyerstein B. Alternative medicine: where's the evidence? Can J Public Health 1997: 88: 149-150.
5. Gray C. Legalize use of marijuana for medical purposes, MDs and patients plead. CMAJ 1998: 158: 373-375.
6. Gruber AJ. Marijuana and cannabinoid abuse. Pharmaceutical News 2000: 7: 30-32.
7. Voth EA, Schwartz RH. Medical applications of delta-9-tetrahydrocannabinol and marijuana. Ann Intern Med 1997: 126: 791-798.
8. Smith DE. Review of the American Medical Association Council on Scientific Affairs Report on medical marijuana. J Psychoactive Drugs 1998: 30: 127-136.
9. Ashton CH, Morgan DR (Eds). Therapeutic uses of cannabis. Amsterdam: British Medical Association. 1997.
10. Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997: 38: 44-48.
11. Meinck HM, Schonle PW, Conrad B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 1989: 236: 120-122.
12. Greenberg HS, Werness SAS, Pugh JE, et al. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther 1994: 55: 324-328.
13. Petro DJ, Ellenberger C. Treatment of human spasticity with delta-9-tetrahydrocannabinol. J Clin Pharmacol 1981: 21: 413S-416S.
14. Clifford DB. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 1983: 13: 669-671.
15. Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1988: 7: 39-50.
16. Martyn CN, Illis LS, Thom J. Nabilone in the treatment of multiple sclerosis. Lancet 1995: 345: 579.
17. Brenneisen R, Egli A, Elsohly MA, Henn V, Spiess Y. The effect of orally and rectally administered delta-9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 1996: 34: 446-452.
18. Killestein J, Hoogervorst EJL, Reif M, et al. Safety, tolerability and efficacy of orally administered cannabinoids in multiple sclerosis. Neurology 2002: 58: 1404-1407.
19. Stenager E, Stenager EN, Knudsen L, Jensen K. The use of non-medical/alternative treatment in multiple sclerosis: a 5 year follow-up study. Acta Neurol Belg 1995: 95: 18-22.
20. Pleines J. Multiple sclerosis and alternative medicine. Axon 1992: 13: 123-124.
21. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983: 33: 1444-1452.
22. Stata statistical software: release 6.0 [computer program]. College Station TX: Stata Corporation: 1999.
23. Canadian Center on Substance Abuse (CCSA). Canadian profile: alcohol, tobacco and other drugs, Ottawa. CCSA. 1999.
24. Arnold T. Canadians favour the use of medical marijuana. National Post 138 Ed. 1999 Apr 7; 1.
25. Chang AE, Shiling DJ, Stillman RC, et al. Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate: a prospective, randomized evaluation. Ann Intern Med 1979: 91: 819-824.
26. Ohisson A, Lindgren AE, Whalen A. Plasma delta-9-tetrahydro-cannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 1980: 28: 409-416.
27. Zuardi AW, Shirakawa I, Finkelbarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta-9-THC in normal subjects. Psychopharmacology 1982: 76: 245-250.
28. Hall W, Solowij N. Adverse effects of cannabis. Lancet 1998: 352: 1611-1616.
29. Feldman HW, Mandel J. Providing medicinal marijuana: the importance of cannabis clubs. J Psychoactive Drugs 1998: 30: 179-186.
30. Stebbins RA. Tolerable differences: living with deviance. 2nd ed. Toronto: McGraw-Hill Ryerson Limited; 1996.
31. Doblin RE, Kleiman MAR. Marijuana as anti-emetic medicine: a survey of oncologists' experiences and attitudes. J Clin Oncol 1991: 9: 1314-1319.
32. Sibbald B. A primer for patient's use of medical marijuana (news). CMAJ 2001: 165: 329.